×
About 4,168 results

ALLMedicine™ Clear Cell Renal Cell Carcinoma Center

Research & Reviews  1,553 results

Special issue "The advance of solid tumor research in China": Multi-omics analysis base...
https://doi.org/10.1002/ijc.34121
International Journal of Cancer; Tian X, Wang Y et. al.

May 18th, 2022 - In clear cell renal cell carcinoma (ccRCC), glycolysis is enhanced mainly because of the increased expression of key enzymes in glycolysis. Hence, the discovery of new molecular biomarkers for glycolysis may help guide and establish a precise syst...

Clear Cell Renal Cell Carcinoma with Immunotherapy Effect Mimicking Xanthogranulomatous...
https://doi.org/10.1177/10668969221101873
International Journal of Surgical Pathology; Wang Y, Ganesan S et. al.

May 17th, 2022 - Renal cell carcinoma is now increasingly treated with checkpoint inhibitor therapy, predominantly in the metastatic setting or occasionally in the adjuvant setting; however, there is little published histopathology data demonstrating the post-ther...

Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic...
https://doi.org/10.1001/jamanetworkopen.2022.12347
JAMA Network Open; Chakiryan NH, Gore LR et. al.

May 17th, 2022 - Level I evidence has failed to demonstrate an overall survival (OS) advantage for cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma (ccRCC) in the modern era, which is at odds with observational studies reportin...

Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With A...
https://doi.org/10.46883/2022.25920957
Oncology (Williston Park, N.Y.); Panian J, Pan E et. al.

May 17th, 2022 - A Mexican woman, aged 60 years, presented with fevers and abdominal pain. She had initially presented to an outside emergency department with weakness, malaise, nausea, vomiting, tachycardia to 110s, and fever to 102 °F. Her medical history was re...

Treatment Strategies in Metastatic Renal Cancer: Dose Titration in Clear Cell Renal Cel...
https://doi.org/10.1016/j.eururo.2022.04.018
European Urology; Brown JE, Symeonides SN

May 17th, 2022 - Treatment Strategies in Metastatic Renal Cancer: Dose Titration in Clear Cell Renal Cell Carcinoma.|2022|Brown JE,Symeonides SN,|

see more →

Guidelines  1 results

New developments in existing WHO entities and evolving molecular concepts: The Genitour...
https://doi.org/10.1038/s41379-021-00779-w
Modern Pathology : an Official Journal of the United Stat... Trpkov K, Hes O et. al.

Mar 6th, 2021 - The Genitourinary Pathology Society (GUPS) reviewed recent advances in renal neoplasia, particularly post-2016 World Health Organization (WHO) classification, to provide an update on existing entities, including diagnostic criteria, molecular corr...

see more →

Clinicaltrials.gov  44 results

A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT04028245

May 11th, 2022 - Patients with localized and non-metastatic Renal Cell Carcinoma (RCC) represent an "at-need" population who would benefit from immunotherapy earlier in their disease course with a programmed cell death protein 1(PD-1) therapy combined with a secon...

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT04300140

May 10th, 2022 - This is a Phase 1b/2 study of AVB-S6-500 designed to evaluate the safety and efficacy of AVB-S6-500 in combination with cabozantinib, AVB-S6-500 in combination with cabozantinib and nivolumab and AVB-S6-500 monotherapy in subjects with advanced or...

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
https://clinicaltrials.gov/ct2/show/NCT04626479

Apr 21st, 2022 - Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03A is to evaluate the safety and efficacy of experimental c...

Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02724878

Apr 12th, 2022 - This research study is a Phase II clinical trial. In this research the investigators are studying the combination of Atezolizumab with Bevacizumab. Participants will receive both vascular endothelial targeted therapy and immunotherapy. The FDA (th...

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
https://clinicaltrials.gov/ct2/show/NCT04322955

Apr 4th, 2022 - People with metastatic kidney cancer are usually treated with medications to slow the growth of the cancer. In addition, people who still have the kidney where the cancer started may have the kidney removed during the course of treatment. This sur...

see more →

News  69 results

Combination Sitravatinib and Nivolumab Boosts Outcomes in Advanced Kidney Cancer
https://www.medscape.com/viewarticle/972855

Apr 28th, 2022 - NEW YORK (Reuters Health) - In patients with advanced clear cell renal cell carcinoma (ccRCC), an optimal sitravatinib dose combined with a fixed dose of nivolumab improved outcomes in a phase 1-2 trial. "A surprising finding was that patients tre...

Patient Profile Presentation: A 61-Year-Old Man with Advanced Renal Cell Carcinoma
https://www.onclive.com/view/case-presentation-a-61-year-old-man-with-advanced-renal-cell-carcinoma

Mar 7th, 2022 - Eric Jonasch, MD: Hello, and welcome to this OncLive® My Treatment Approach program titled Improving Outcomes in Advanced Renal Cell Carcinoma: Translating Evidence to Clinical Practice. I’m Eric Jonasch, a professor in the department of genitouri...

Immune Cell–Related Parameters May Serve as Biomarkers for Response to Nivolumab/Ipilimumab in Clear Cell RCC
https://www.onclive.com/view/nivolumab-and-ipilimumab-response-rates-based-on-immune-cell-factors-in-advanced-rcc

Feb 20th, 2022 - Efficacy rates generated by the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) vary based on certain immune-cell related parameters in patients with advanced or metastatic clear cell renal cell carcinoma, according to an analysis of the...

Dr. Bupathi on Considerations for Second-Line Sequencing in RCC
https://www.onclive.com/view/dr-bupathi-on-considerations-for-second-line-sequencing-in-rcc

Nov 23rd, 2021 - Manojkumar Bupathi, MD, MS, medical oncologist, Rocky Mountain Cancer Centers, discusses considerations for second-line treatment sequencing in clear cell renal cell carcinoma (RCC). A main consideration in sequencing therapy for patients with RC...

Investigators Tackle New NSCLC Target With Glutaminase Inhibitor
https://www.onclive.com/view/investigators-tackle-new-nsclc-target-with-glutaminase-inhibitor

Oct 6th, 2021 - Telaglenastat (CB-839), a novel drug that targets a key metabolic pathway, has shown encouraging antitumor activity in several cancer types. Now, investigators have launched the phase 2 KEAPSAKE trial to evaluate the agent in combination with stan...

see more →